Class summary at a glance.

Every drug in the Glinide class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $29.5Mcombined across class
Total Rx claims: 771K240K unique beneficiaries
Generic mfrs (active): 10across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Repaglinide

548K Part D claims (CY24) · 171K beneficiaries · First FDA approval: 2013-11-22

4 generic mfrs 0 plans require PA

Low NADAC$0.080

→

Avg plan cost$0.082

Part D spend $17.5M 1× spread, current vs floor

Class share

59%

of class CY24 spend

View profile →

Nateglinide

224K Part D claims (CY24) · 70K beneficiaries · First FDA approval: 2009-09-09

6 generic mfrs 0 plans require PA

Low NADAC$0.178

→

Avg plan cost$0.216

Part D spend $12.1M 1× spread, current vs floor

Class share

41%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.